Discover 3,032 paid clinical trials in Thousand Oaks, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,032
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
for
Carcinoma, Non-Small-Cell Lung Cancer,
Location: Beverly Hills CA, Tyler TX, Pittsburgh PA, Norfolk VA
Sponsor: Kiromic BioPharma Inc.
Sex: All
Age: 18+
Code: NCT06069570
Phase1, Recruiting
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
for
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
Location: Beverly Hills CA, Fountain Valley CA, Dallas TX,
Sponsor: Lantern Pharma Inc.
Sex: All
Age: 18+
Code: NCT05456256
Phase2, Recruiting
Personalized Health Self-Management Training for Colorectal Cancer Survivors
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Duarte CA, Irvine CA
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT06910761
Phase2, Recruiting
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
for
Head and Neck Squamous Cell Carcinoma,
Location: Los Angeles CA, Bakersfield CA, Surprise AZ, Peoria AZ,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06992427
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
for
Clostridoides Difficile Associated Disease
Location: Toluca Lake CA, Los Angeles CA, Ontario CA,
Sponsor: Pfizer
Sex: All
Age: 65+
Code: NCT07282665
Phase3, Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer